A low-cost and open-hardware portable 3-electrode sleep monitoring device.

To continue sleep research activities during the lockdown resulting from the COVID-19 pandemic, experiments that were previously conducted in laboratories were shifted to the homes of volunteers. Furthermore, for extensive data collection, it is necessary to use a large number of portable devices. Hence, to achieve these objectives, we developed a low-cost and open-source portable monitor (PM) device capable of acquiring electroencephalographic (EEG) signals using the popular ESP32 microcontroller.

A New Ready-to-Eat Product Based on Enzymatically Peeled 'Hernandina' Clementine Segments and Citrus Syrup.

Ready-to-eat fresh fruit have an increasing presence in international markets due to their convenience and health benefits. However, these products are highly perishable and efficient technologies to increase their shelf life are needed. In the present research, different citrus fruit species and cultivars from organic farming were assessed to obtain enzymatically peeled citrus segments.

Preliminary approach to evaluate the drug-drug interaction potential of EST73502, a dual µ-opioid receptor partial agonist and σ1 receptor antagonist.

The potential for drug-drug interactions (DDI) of EST73502 was preliminary explored . EST73502 is a new chemical entity intended for oral pain treatment with dual sigma-1 receptor (σR) antagonism and μ-opioid receptor (MOR) partial agonism, that presents a promising potent analgesic activity.Several enzymes were involved in EST73502 metabolism catalysing the formation of different metabolites, CYP3A4 and CYP2D6 being the main ones.

Preliminary assessment of pharmacokinetic drug-drug interactions of EST64401 and EST64514, two sigma-1 receptor antagonists.

EST64401 and EST64514 are two selective sigma-1 receptor ligands that showed a good profile in a lead optimization process for oral pain treatment. Their potential for pharmacokinetic-based drug-drug interactions was assessed to anticipate clinical interactions.Both compounds showed a low potential for CYP inhibition with percentages of inhibition <50% at 1 µM in recombinant human CYPs (CYP1A2, 2C9, 2C19, 2D6 and 3A4) and IC ≥75 µM for CYP3A4 and 2D6 in human liver microsomes.